No effect of escitalopram versus placebo on brain-derived neurotrophic factor in healthy individuals: A randomised trial

Acta Neuropsychiatrica

Volumn 28, Issue 2, 2016, Pages 101-109

  Knorr, Ulla ^a,b   Koefoed, Pernille ^a   Soendergaard, Mia H Greisen ^a   Vinberg, Maj ^a   Gether, Ulrik ^b   Gluud, Christian ^a   Wetterslev, Jørn ^a   Winkel, Per ^a   Kessing, Lars V ^a  

^a University of Copenhagen   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

affective disorders; brain derived neurotrophic factor (BDNF); escitalopram; healthy; trial

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; ESCITALOPRAM; MESSENGER RNA; PLACEBO; ANTIDEPRESSANT AGENT; BRAIN-DERIVED NEUROTROPHIC FACTOR, HUMAN; CITALOPRAM;

ADULT; ARTICLE; BDNF GENE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; FEMALE; FIRST DEGREE RELATIVE; GENE EXPRESSION; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; BIOSYNTHESIS; BLOOD; DEPRESSION; DOUBLE BLIND PROCEDURE; FAMILY HEALTH; METABOLISM; YOUNG ADULT;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BRAIN-DERIVED NEUROTROPHIC FACTOR; CITALOPRAM; DEPRESSION; DOUBLE-BLIND METHOD; FAMILY HEALTH; FEMALE; HEALTHY VOLUNTEERS; HUMANS; MALE; YOUNG ADULT;

EID: 84947087531     PISSN: 09242708     EISSN: 16015215     Source Type: Journal    
DOI: 10.1017/neu.2015.55     Document Type: Article

References (34)

1. DUMAN RS, HENINGER GR, NESTLER EJ. A molecular and cellular theory of depression. Arch Gen Psychiatry 1997;54:597-606.
2. CAI S, HUANG S, HAO W. New hypothesis and treatment targets of depression: an integrated view of key findings. Neurosci Bull 2015;3:161-174.
3. MOSSNER R, MIKOVA O, KOUTSILIERI E et al. Consensus paper of the WFSBP Task Force on Biological Markers: biological markers in depression. World J Biol Psychiatry 2007;8:141-174.
4. FRAZIER TW, YOUNGSTROM EA, FRANKEL BA et al. Candidate gene associations with mood disorder, cognitive vulnerability, and fronto-limbic volumes. Brain Behav 2014;4:418-430.
5. MARTINEZ-LEVY GA, CRUZ-FUENTES CS. Genetic and epigenetic regulation of the brain-derived neurotrophic factor in the central nervous system. Yale J Biol Med 2014;87:173-186.
6. SCHMIDT HD, DUMAN RS. Peripheral BDNF produces antidepressant-like effects in cellular and behavioral models. Neuropsychopharmacology 2010;35:2378-2391.
7. TONGIORGI E. Activity-dependent expression of brain-derived neurotrophic factor in dendrites: facts and open questions. Neurosci Res 2008;61:335-346.
8. MOLENDIJK ML, SPINHOVEN P, POLAK M, BUS BA, PENNINX BW, ELZINGA BM. Serum BDNF concentrations as peripheral manifestations of depression: evidence from a systematic review and meta-analyses on 179 associations (N = 9484). Mol Psychiatry 2014;19:791-800.
9. YOSHIDA T, ISHIKAWA M, NIITSU T et al. Decreased serum levels of mature brain-derived neurotrophic factor (BDNF), but not its precursor proBDNF, in patients with major depressive disorder. PLoS One 2012;7:e42676.
10. ZHOU L, XIONG J, LIM Y et al. Upregulation of blood proBDNF and its receptors in major depression. J Affect Disord 2013;150:776-784.
11. MOLENDIJK ML, BUS BA, SPINHOVEN P et al. Serum levels of brain-derived neurotrophic factor in major depressive disorder: state-trait issues, clinical features and pharmacological treatment. Mol Psychiatry 2011;16:1088-1095.
12. HASSELBALCH BJ, KNORR U, BENNIKE B, HASSELBALCH SG, SONDERGAARD MH, KESSING LV. Decreased levels of brain-derived neurotrophic factor in the remitted state of unipolar depressive disorder. Acta Psychiatr Scand 2012;126:157-164.
13. DUCLOT F, KABBAJ M. Epigenetic mechanisms underlying the role of brain-derived neurotrophic factor in depression and response to antidepressants. J Exp Biol 2015;218(Pt 1): 21-31.
14. POLYAKOVA M, STUKE K, SCHUEMBERG K, MUELLER K, SCHOENKNECHT P, SCHROETER ML. BDNF as a biomarker for successful treatment of mood disorders: a systematic & quantitative meta-analysis. J Affect Disord 2014;174C: 432-440.
15. MORILAK DA, FRAZER A. Antidepressants and brain monoaminergic systems: a dimensional approach to understanding their behavioural effects in depression and anxiety disorders. Int J Neuropsychopharmacol 2004;7:193-218.
16. YOSHIMURA R, KISHI T, HORI H et al. Serum proBDNF/BDNF and response to fluvoxamine in drug-naive first-episode major depressive disorder patients. Ann Gen Psychiatry 2014;13:19.
17. CATTANEO A, GENNARELLI M, UHER R et al. Candidate genes expression profile associated with antidepressants response in the GENDEP study: differentiating between baseline 'predictors' and longitudinal 'targets'. Neuropsychopharmacology 2012;38:377-385.
18. HASLER G, DREVETS WC, GOULD TD, GOTTESMAN II, MANJI HK. Toward constructing an endophenotype strategy for bipolar disorders. Biol Psychiatry 2006;60:93-105.
19. KNORR U, VINBERG M, KLOSE M et al. Rationale and design of the participant, investigator, observer, and data-analyst-blinded randomized AGENDA trial on associations between gene-polymorphisms, endophenotypes for depression and antidepressive intervention: the effect of escitalopram versus placebo on the combined dexamethasone-corticotrophine releasing hormone test and other potential endophenotypes in healthy first-degree relatives of persons with depression. Trials 2009;10:66.
20. KNORR U, VINBERG M, HANSEN A et al. Escitalopram and neuroendocrine response in healthy first-degree relatives to depressed patients - a randomized placebo-controlled trial. PLoS One 2011;6:e2124.
21. BOCK C, BUKH JD, VINBERG M, GETHER U, KESSING LV. Validity of the diagnosis of a single depressive episode in a case register. Clin Pract Epidemiol Ment Health 2009;5:4.
22. WING JK, BABOR T, BRUGHA T et al. SCAN. Schedules for Clinical Assessment in Neuropsychiatry. Arch Gen Psychiatry 1990;47:589-593.
23. BECH P, KASTRUP M, RAFAELSEN OJ. Mini-compendium of rating scales for states of anxiety depression mania schizophrenia with corresponding DSM-III syndromes. Acta Psychiatr Scand Suppl 1986;326:1-37.
24. KENDLER KS, KESSLER RC, WALTERS EE et al. Stressful life events, genetic liability, and onset of an episode of major depression in women. Am J Psychiatry 1995;152:833-842.
25. TRAJKOVSKA V, VINBERG M, AZNAR S, KNUDSEN GM, KESSING LV. Whole blood BDNF levels in healthy twins discordant for affective disorder: association to life events and neuroticism. J Affect Disord 2008;108:165-169.
26. TRAJKOVSKA V, MARCUSSEN AB, VINBERG M, HARTVIG P, AZNAR S, KNUDSEN GM. Measurements of brain-derived neurotrophic factor: methodological aspects and demographical data. Brain Res Bull 2007;73:143-149.
27. HOLM S. A simple sequentially rejective multiple test procedure. Scand J Stat 1979;6:65-70.
28. YASUI-FURUKORI N, TSUCHIMINE S, NAKAGAMI T et al. Association between plasma paroxetine concentration and changes in plasma brain-derived neurotrophic factor levels in patients with major depressive disorder. Hum Psychopharmacol 2011;26:194-200.
29. MODELL S, LAUER CJ, SCHREIBER W, HUBER J, KRIEG JC, HOLSBOER F. Hormonal response pattern in the combined DEX-CRH test is stable over time in subjects at high familial risk for affective disorders. Neuropsychopharmacology 1998;18:253-262.
30. KNORR U, VINBERG M, KESSING LV, WETTERSLEV J. Salivary cortisol in depressed patients versus control persons: a systematic review and meta-analysis. Psychoneuroendocrinology 2010;35:1275-1286.
31. HAASTRUP E, KNORR U, ERIKSTRUP C, KESSING LV, ULLUM H. No evidence for an anti-inflammatory effect of escitalopram intervention in healthy individuals with a family history of depression. J Neuroimmunol 2012;243:69-72.
32. JING L, BU M. Role of macrophage migration inhibitory factor in glucocorticoid release and glucocorticoid receptor function in rats. Ann Clin Lab Sci 2011;41:14-19.
33. TURNER EH, MATTHEWS AM, LINARDATOS E, TELL RA, ROSENTHAL R. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med 2008;358:252-260.
34. SODERSTEN K, PALSSON E, ISHIMA T et al. Abnormality in serum levels of mature brain-derived neurotrophic factor (BDNF) and its precursor proBDNF in mood-stabilized patients with bipolar disorder: a study of two independent cohorts. J Affect Disord 2014;160:1-9.